Preliminary research indicate that this peptide – a dual agonist of GLP-1 and GIP receptors – presents a significant breakthrough in metabolic loss therapies. Beyond existing therapies, this dual-action compound shows to influence appetite and calorie expenditure via separate routes. While further investigation is needed , current results raise